Back to top
more

Insulet Corporation (PODD)

(Delayed Data from NSDQ)

$272.51 USD

272.51
188,504

+5.66 (2.12%)

Updated Jul 28, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.57%
2Buy19.14%
3Hold10.74%
4Sell6.46%
5Strong Sell3.16%
S&P50011.27%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 25% (190 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Brokerage Reports

Research for PODD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Insulet Corporation [PODD]

Reports for Purchase

Showing records 101 - 120 ( 249 total )

Company: Insulet Corporation

Industry: Medical - Products

Record: 101

09/29/2016

Industry Report

Pages: 6

670G Approval Significantly Ahead of Expectations, but Launch Date is in Line; Impact to Competitors to be Minor

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 102

09/29/2016

Industry Report

Pages: 6

670G Approval Significantly Ahead of Expectations, but Launch Date is in Line; Impact to Competitors to be Minor

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 103

09/21/2016

Daily Note

Pages: 5

Monthly Neulasta Onpro Prescription Tracker: - Sequential Decline in August Reflects Historic Pattern After a Strong July; Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 104

09/05/2016

Industry Report

Pages: 10

Diabetes Technology Panel Highlights The Opportunities That Lie Ahead

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 105

08/24/2016

Daily Note

Pages: 5

Monthly Neulasta Onpro Kit Prescription Tracker Points to Significant Sequential Share Gain (However July Data May Be an Anomaly); Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 106

08/17/2016

Industry Report

Pages: 23

HEALTHCARE - 2016 PacGrow Healthcare Conference Day 1

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 107

08/17/2016

Industry Report

Pages: 23

Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 108

08/17/2016

Industry Report

Pages: 17

Medical Devices - Day 1: Key Takeaways from the PacGrow Healthcare Conference

Provider: Wedbush Securities Inc.

Price: 50.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 109

08/04/2016

Company Report

Pages: 8

2Q Results Highlighted by a Multitude of Positive Surprises; Increasing PT to $48 - Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 110

07/28/2016

Daily Note

Pages: 4

Insulet Corp. with OUTPERFORM: Onpro Kit exits 2Q with 40% share of Neulasta franchise and Continues to Grow

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 111

07/20/2016

Daily Note

Pages: 5

Insulet Corp.with OUTPERFORM: Monthly Neulasta Onpro Kit Prescription Tracker Points To Further Share Gains; Setback To Novartis Biosimilar Positive For OPK; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 112

07/15/2016

Daily Note

Pages: 41

Medical Devices: 2Q16 MedTech Preview: Stable Trends and Healthy Underlying Fundamentals

Provider: Wedbush Securities Inc.

Price: 100.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 113

07/10/2016

Industry Report

Pages: 6

Diabetes: Artificial Pancreas Workshop Provides Insights On the Future of the Diabetes Market

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 114

06/22/2016

Daily Note

Pages: 5

Monthly Neulasta Onpro Kit Prescription Tracker Points Toward Further Share Gains in May; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 115

06/15/2016

Daily Note

Pages: 9

American Diabetes Association Meeting Suggests a Diabetes Technology Renaissance Is Coming; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 116

05/25/2016

Daily Note

Pages: 5

Neulasta Onpro Kit Prescriptions Continue to Gain Share in April; Maintain OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 117

05/20/2016

Daily Note

Pages: 5

International OmniPod Demand Expected to Remain Robust; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 118

05/16/2016

Industry Report

Pages: 7

MDT/UHC Insulin Pump Agreement Could Become A Significant POSITIVE for the Other

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 119

05/03/2016

Daily Note

Pages: 9

Volatility in Diabetes Stocks Following UNH/MDT Agreement Creates Buying Opportunity; Reiterate OUTPERFORM on DXCM, PODD, TNDM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 120

04/29/2016

Company Report

Pages: 8

Steady Improvements with Healthy Underlying Momentum Across All Segments; Reiterate OUTPERFORM

Provider: Wedbush Securities Inc.

Price: 25.00

Research Provided by a Third Party